Evidence map›Paper›PMID 30739283›Full record

ArticleJournal of natural medicines2019

Analyses of the possible anti-tumor effect of yokukansan.

Cheolsun Han, Miho Kawata, Yusuke Hamada, Takashige Kondo, Junna Wada, Katsunori Asano, Hitoshi Makabe, Katsuhide Igarashi, Naoko Kuzumaki, Michiko Narita and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Cheolsun HanDepartment of Hospital Administration, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan. cheolsun.han.1229@gmail.com.
Miho KawataDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Yusuke HamadaDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Takashige KondoDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Junna WadaDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Katsunori AsanoDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Hitoshi MakabeDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Katsuhide IgarashiLife Science Tokyo Advanced Research Center (L-StaR), Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Naoko KuzumakiDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Michiko NaritaDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan.
Hiroyuki KobayashiDepartment of Hospital Administration, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
Minoru NaritaDepartment of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Science, Shinagawa-ku, Tokyo, 142-8501, Japan. narita@hoshi.ac.jp.
Hoshi University · JPJuntendo University · JPFujita Health University · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology S1411019
6 · The paper itself

Abstract

The Kampo medicine yokukansan (YKS) has a wide variety of properties such as anxiolytic, anti-inflammatory and analgesic effects, and is also thought to regulate tumor suppression. In this study, we investigated the anti-tumor effect of YKS. We used Lewis lung carcinoma (LLC)-bearing mice that were fed food pellets containing YKS and then performed a fecal microbiota analysis, a microarray analysis for microRNAs (miRNAs) and an in vitro anti-tumor assay. The fecal microbiota analysis revealed that treatment with YKS partly reversed changes in the microbiota composition due to LLC implantation. Furthermore, a miRNA array analysis using blood serum showed that treatment with YKS restored the levels of miR-133a-3p/133b-3p, miR-1a-3p and miR-342-3p following LLC implantation to normal levels. A TargetScan analysis revealed that the epidermal growth factor receptor 1 signaling pathway is one of the major target pathways for these miRNAs. Furthermore, treatment with YKS restored the levels of miR-200b-3p and miR-200c-3p, a recognized mediator of cancer progression and controller of emotion, in the hypothalamus of mice bearing LLC. An in vitro assay revealed that a mixture of pachymic acid, saikosaponins a and d and isoliquiritigenin, which are all contained in YKS, exerted direct and additive anti-tumor effects. The present findings constitute novel evidence that YKS may exert an anti-tumor effect by reversing changes in the fecal microbiota and miRNAs circulating in the blood serum and hypothalamus, and the compounds found in YKS could have direct and additive anti-tumor effects.

Indexed as

AnimalsAnti-Anxiety AgentsHumansMaleMedicine, KampoMiceNeoplasmsAnti-Anxiety AgentsHypothalamusMicrobiotaMicroRNATumorYokukansan

Identifiers

PMID30739283
OpenAlexW2912855190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.